Medica 2015 Introduction

Title Page

Introduction Presentation

May, 2015

Welcome to Latin America

Introduction presentation

Medica, 2015

Omer Inbar, Managing Director

[email protected]

Marpel Pharma Group

• Marpel Pharma Group, established in 2000 and headquartered in San Jose, Costa Rica, is a leading distributor of Pharmaceuticals and Medical Devices in Latin America.

• With additional offices in Mexico, Guatemala, El Salvador, Honduras & Argentina, Marpel utilizes its global infrastructure to provide its customers cutting edge products and outstanding service.

• Marpel Pharma operates two subsidiary companies: Latin Health Group & Latin Health International covering Mexico, Central America & the Andean region.

Marpel Pharma Group

Marpel Pharma specializes in the distribution of pharmaceuticals. The company specializes in working with government dominated markets, registering and selling over 200 products in fields including: CNS, Respiratory, Gastrointestinal, Antibiotics.

Marpel Pharma has established operations in India & China geared to ensure local markets with the highest quality generic pharmaceuticals.

Latin Health Group – Devices Sales

Latin Health Group is the Medical Devices subsidiary, operating in Central America & Mexico in the following divisions:

• General surgery & laparoscopy• Infection control• Orthopedics, trauma & rehab • Interventional radiology

We exclusively represent over 30 brands including:

Meet some of our team members…

Costa Rica HQ

Guatemala Honduras El Salvador Argentina

33 countries, 600 million person population, geographically covering 14% of the planet’s surface.

Brazil & Mexico, the two largest markets in population and GDP, representing around 50% of LATAM’s GDP.

Introduction to Latin America

Source: UN, IMF

Top ten Latin American countries GDP at $6 trillion is the fourth largest economy in the world.

Low GDP/Capita vs. OECD but significantly higher than India & China.

Strong increases in HealthCare expenditures, tech acceptance.

2012

OECD 72.2

LATAM 41

China 42.3

India 12.6

Russia 63.8

Internet Users, per 100 people

Introduction to Latin America

Source: UN, IMF

Strong Urbanization Trends

People per Square

Kilometre

Highly Urban Countries More than 200 people

Medium-High Urban Countries 100 – 200 people

Medium Urban Countries 50 – 100 people

Low-Medium Urban Countries 10 – 50 people

Low Urban Countries Less than 10 people

Mexico CityPopulation 2025:

24.6 millionGDP 2025:

$713.5 billion

BogotaPopulation

2025:11.4 millionGDP 2025:

$298.0 billion

Rio de JaneiroPopulation 2025:


$327.1 billion

Buenos AiresPopulation 2025:


$327.1 billion

Sao PauloPopulation 2025:


$643.9 billionSantiagoPopulation 2025:

7.1 million

Belo HorizontePopulation 2025:

6.6 million

GuadalajaraPopulation 2025:

5.7 million

Source: United Nations, Department of Economic and Social Affairs Statistics, Frost & Sullivan and other regional and country level statistics bureau

LimaPopulation

2025:11.5 million

Mega Cities

in 2025Emerging Mega Cities

Mega Cities:

By 2025, it is

expected that

86% of the

population will

be living in

urban areas.

Latin America Medical Devices Market

Total Imports Imports as % of Market

Brazil $2.8B 72%

Mexico $2.5B 95%

Argentina $0.4B 89%

Colombia $0.5B 86%

Venezuela $0.9B 95%

Chile $0.4B 96%

CAGR 2013-2017 is estimated at 7.7%, 3rd

fastest in the world.

Latin Health International

The Vision: To be the gateway for Medical Devices & Pharmaceuticals for all of Latin America.


Outside of Brazil & Mexico, Latin

America markets are low priority for the small-medium

sized manufacturer.

High diversification makes it

challenging for manufacturers to

address each territory

individually.

The Background The Opportunity

Our philosophy is to create a REAL win-win situation when we are dealing with manufacturers:

- Establish & manage a distribution network for the manufacturer.

- Manage product education and marketing activities alongside the distributor.

- Utilize market experience and know-how, bridge cultural differences.

- Create a business model that is 100% success driven.


Each product will go through a process that begins with initial screening and ends with our account management of the product.

Initially in Israel, looking to expand to EU & US.


Screening, local

market evaluation

Cross country

evaluation

Territory Selection

Agreements & Reg.

Initial Sales

Account Mgmt.

Model Benefits

LHI

• Dramatically reduced inventory and operational expenses.

• Highly profitable

• Geographical location

• Exposure to new markets

• Utilize market know-how

Manufacturers

• Success model

• Low management time requirements.

• Diversification of global footprint.

• Regulatory support.

• Maintain solid visibility.

First Target: Israel HealthCare Technologies

Targeting Israeli Market – Why?

Breakdown of Sub-Segments Med Devices

Targeting Israel Market

Global VC Investments 2010-2014

Israel VC Investments in Life Sciences

Global HealthCare Companies in Israel

Product Portfolio

An inflatable balloon retractor indicated to retract organs for improved vision during laparoscopic surgery.

IceSense 3 System IceCure Medical has developed a third generation cryoablation system for breast tumors that easier, faster and safer than competition.

Product Portfolio

DASH – Disposable, Absorbent, Secure Hold is an absorbent, soft tissue retractor comprised of a silicone coated steel mesh.

The device is being used in a wide range of surgical procedures (gynecology, urology, general, vascular) of the abdomen.

Benefits include: Superior exposure & access of surgical field, ease of use, reduced risk of retained foreign body post op.

Product Portfolio

Product Portfolio

First Total Lift Standing Bed in Market- Important addition to early mobility trends- Indications include ICU, burn units, pulmonary, bariatrics.

Product Portfolio

An ultrasound-based GPS device created to accurately track fetal station and position upon entering the mother’s pelvis. Removes the need for blind interpretation of cervical dilation and fetal positioning by maternity care providers.

Product Portfolio

A line of Dynamic Tissue systems that utilize the skin & body’s anatomical processes to dramatically improve wound closure outcomes:

- Next step in closure of difficult to close wounds

- Improve aesthical outcome of suture site.

Product Portfolio

Introduction Presentation

May, 2015

Thank You!!!

Medica 2015 Introduction

Documents

Transcript of Medica 2015 Introduction